Sep 25, 2023
Harmony Biosciences Holdings, Inc
HRMY
Statistics
| $34.28 | Share Price |
| $68.00 | Fair Value |
| -49.59% | Price vs Fair Value |
| $2.0 B | Market Cap |
| 24.0% | 3yr Avg Revenue Growth |
| 18.7% | Projected Sales Growth Next Year |
| 28.2% | Free Cash Flow ROIC |
 | Rising Revenues |
| Recurring Revenues |
 | Regulatory Barriers Moat |
Stock Research and Updates
Research Article
Updates
Harmony Looks On Track After Q2 Results
Aug 16, 2024
Updates: HRMY, MELI, SWAV
Feb 28, 2024
Fair Value Calculation Assumptions
Using a discounted free cash flow model with the following assumptions, the Fair Value estimate for Harmony Biosciences Holdings, Inc (HRMY) is $68.00.
| 29.0% | Free Cash Flow Margin |
| 13.5% | Discount Rate / Required Rate of Return |
| 16.4% | Average Annual Revenue Growth (Years 1-5) |
| 1.3% | Average Annual Share Dilution (Years 1-5) |
| 9.2% | Average Annual Revenue Growth (Years 6-10) |
| 1.6% | Average Annual Share Dilution (Years 6-10) |
| 6.0% | Terminal Growth Rate |
| $63.50 | Sum of Discounted Free Cash Flows |
| $4.69 | Net "Excess" Cash/Debt Per Share |
| $68.00 | Fair Value Estimate (rounded) |
Last updated Nov 12, 2024
Information contained on this website represents only the opinions of the author and should not be used as the sole basis for investing decisions. By using this site, you agree to all statements in the Site Policy.
Watch List
| S | 9.41% |
| CRWD | 73.34% |
| SEMR | -15.86% |
| SNOW | 15.48% |
| TSM | -1.89% |
vs. Fair Value Estimates
Buy List
| GOOG | -33.69% |
| NYAX | -61.69% |
| ASR | -31.25% |
| PAYC | -28.54% |
| HRMY | -49.59% |
| YOU | -45.59% |
| MELI | -30.27% |
| ADBE | -30.99% |
vs. Fair Value Estimates
Hold List
| MSFT | -21.19% |
| ODD | -23.90% |
| FLYW | 4.57% |
| CELH | -15.59% |
| TOST | 31.86% |
| CPNG | -2.38% |
| HIMS | -6.43% |
| MNDY | 15.47% |
| GLBE | 16.55% |
| ZS | 18.59% |
| V | -11.99% |
| ADSK | 11.66% |
| NOW | 50.93% |
| ABNB | -19.63% |
| FTNT | 4.51% |
| TEAM | 14.85% |
vs. Fair Value Estimates